Brighton Jones LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 3.3% during the second quarter, according to its most recent filing with the SEC. The firm owned 40,027 shares of the biopharmaceutical company’s stock after selling 1,351 shares during the period. Brighton Jones LLC’s holdings in Pfizer were worth $1,409,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in PFE. Ronna Sue Cohen boosted its stake in Pfizer by 0.4% in the second quarter. Ronna Sue Cohen now owns 7,881 shares of the biopharmaceutical company’s stock valued at $277,000 after buying an additional 35 shares in the last quarter. Forte Capital LLC ADV raised its stake in shares of Pfizer by 0.4% in the first quarter. Forte Capital LLC ADV now owns 8,589 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 36 shares during the last quarter. Naples Global Advisors LLC raised its stake in shares of Pfizer by 0.4% in the second quarter. Naples Global Advisors LLC now owns 24,327 shares of the biopharmaceutical company’s stock valued at $857,000 after buying an additional 85 shares during the last quarter. Lincoln Capital LLC raised its stake in shares of Pfizer by 1.1% in the second quarter. Lincoln Capital LLC now owns 8,443 shares of the biopharmaceutical company’s stock valued at $297,000 after buying an additional 94 shares during the last quarter. Finally, Donald L. Hagan LLC raised its stake in shares of Pfizer by 0.9% in the second quarter. Donald L. Hagan LLC now owns 11,006 shares of the biopharmaceutical company’s stock valued at $388,000 after buying an additional 97 shares during the last quarter. 69.65% of the stock is currently owned by institutional investors.
Pfizer Inc. (NYSE:PFE) traded down 0.003% during trading on Tuesday, hitting $33.679. 11,566,457 shares of the stock were exchanged. The company has a 50-day moving average price of $34.44 and a 200 day moving average price of $34.14. The firm has a market capitalization of $204.29 billion, a price-to-earnings ratio of 29.857 and a beta of 0.86. Pfizer Inc. has a 1-year low of $28.25 and a 1-year high of $37.39.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.02. The business had revenue of $13.10 billion for the quarter, compared to analysts’ expectations of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.56 EPS. Equities analysts predict that Pfizer Inc. will post $2.46 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be paid a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 3.56%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s dividend payout ratio is currently 95.24%.
Several equities research analysts have issued reports on PFE shares. Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $36.89 price target on the stock in a research note on Tuesday, June 7th. Jefferies Group reiterated a “buy” rating and issued a $42.00 price target (up from $41.00) on shares of Pfizer in a research note on Tuesday, June 14th. Deutsche Bank AG reiterated a “buy” rating on shares of Pfizer in a research note on Wednesday, June 15th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $54.00 price target on shares of Pfizer in a research note on Monday, June 27th. Finally, Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, July 20th. Ten research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $38.78.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.